Briacell Therapeutics -CW27BCTXWPreferred / convertible
13F holders, Q2 2025 (June 30)6holders −1
2new positions
3sold out
$0.07avg. 13F price*
At the end of Q2 2025, 6 institutions reported holding Briacell Therapeutics -CW27 (BCTXW) in their 13F filings, down 1 from Q1 2025. 2 opened new positions and 3 sold out. The largest holders were Redmond Asset Management, LLC ($6K), Two Sigma Securities, LLC ($4K) and Armistice Capital, LLC ($2K).
- Company
- Briacell Therapeutics -CW27
- CUSIP
- 10778Y112
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $1K |
| Exits | 3 | $2K |
All 13F filers, Q1 2025 → Q2 2025: 44,905 shares bought and 19,521 shares sold, net +25,384 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Redmond Asset Management, LLC | — | No change | 75,000 | $6K |
| Two Sigma Securities, LLC | — | Add +73.5% | 53,495 | $4K |
| Armistice Capital, LLC | — | No change | 25,000 | $2K |
| HRT Financial LP | — | New | 21,248 | $1K |
| NFSG Corp | — | New | 1,000 | $75 |
| UBS Group AG | — | Reduce -88.3% | 314 | $24 |
"% of holder's portfolio" is BCTXW's weight in each manager's 13F, not the share of Briacell Therapeutics -CW27 the manager owns.